Horizon Therapeutics PLC (NASDAQ:HZNP) – Analysts at Piper Sandler lowered their FY2022 earnings per share (EPS) estimates for shares of Horizon Therapeutics in a research report issued to clients and investors on Wednesday, June 24th. Piper Sandler analyst D. Amsellem now anticipates that the biopharmaceutical company will post earnings of $4.38 per share for the year, down from their prior forecast of $4.90. Piper Sandler currently has a “Buy” rating and a $61.00 target price on the stock. Piper Sandler also issued estimates for Horizon Therapeutics’ FY2023 earnings at $5.07 EPS.
Other equities analysts have also recently issued reports about the company. BidaskClub raised Horizon Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 24th. Jefferies Financial Group lifted their price objective on Horizon Therapeutics from $47.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Morgan Stanley upped their target price on shares of Horizon Therapeutics from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Bank of America lifted their price target on shares of Horizon Therapeutics from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Finally, Stifel Nicolaus upped their price objective on shares of Horizon Therapeutics from $50.00 to $60.00 in a research note on Friday, May 29th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $45.69.
Shares of NASDAQ:HZNP opened at $55.28 on Monday. The firm has a market capitalization of $10.48 billion, a price-to-earnings ratio of 19.53, a price-to-earnings-growth ratio of 1.97 and a beta of 1.20. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.39 and a quick ratio of 2.27. The business’s 50 day simple moving average is $49.17 and its 200-day simple moving average is $37.95. Horizon Therapeutics has a 12 month low of $22.69 and a 12 month high of $57.34.
Horizon Therapeutics (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.19. The business had revenue of $355.90 million for the quarter, compared to analysts’ expectations of $287.88 million. Horizon Therapeutics had a net margin of 43.06% and a return on equity of 22.52%. The business’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS.
Hedge funds have recently made changes to their positions in the business. Point72 Hong Kong Ltd purchased a new stake in Horizon Therapeutics during the fourth quarter worth approximately $37,000. Harvest Fund Management Co. Ltd purchased a new stake in Horizon Therapeutics during the 1st quarter worth $105,000. Fred Alger Management LLC acquired a new stake in Horizon Therapeutics in the 4th quarter valued at $109,000. Tower Research Capital LLC TRC raised its position in Horizon Therapeutics by 642.1% in the first quarter. Tower Research Capital LLC TRC now owns 3,874 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 3,352 shares during the period. Finally, Penserra Capital Management LLC purchased a new position in Horizon Therapeutics in the fourth quarter valued at about $155,000. 90.08% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Michael G. Grey sold 1,755 shares of Horizon Therapeutics stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total value of $96,525.00. Following the transaction, the director now owns 1,755 shares in the company, valued at $96,525. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeff Kent sold 2,785 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $48.05, for a total value of $133,819.25. Following the sale, the insider now directly owns 65,994 shares of the company’s stock, valued at approximately $3,171,011.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 407,750 shares of company stock valued at $17,110,328. 4.30% of the stock is owned by insiders.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.